These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 34301030)
41. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3 Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784 [TBL] [Abstract][Full Text] [Related]
42. Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action. Arun JK; Vodeti R; Shrivastava B; Bakshi V Adv Pharm Bull; 2020 Jul; 10(3):379-388. PubMed ID: 32665896 [No Abstract] [Full Text] [Related]
43. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines. Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Bhatia S; Al-Harrasi A Drug Dev Ind Pharm; 2021 Jul; 47(7):1112-1120. PubMed ID: 34551665 [TBL] [Abstract][Full Text] [Related]
44. Nanosized ethosomal dispersions for enhanced transdermal delivery of nebivolol using intradermal/transfollicular sustained reservoir: Fouad SA; Khatab ST; Teaima MH; El-Nabarawi MA; Abdelmonem R Pharm Dev Technol; 2024 Jan; 29(1):40-51. PubMed ID: 38078863 [TBL] [Abstract][Full Text] [Related]
45. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. Komesli Y; Burak Ozkaya A; Ugur Ergur B; Kirilmaz L; Karasulu E Drug Dev Ind Pharm; 2019 Aug; 45(8):1292-1305. PubMed ID: 30986085 [TBL] [Abstract][Full Text] [Related]
46. Comparative Evaluation of Solubility, Cytotoxicity and Photostability Studies of Resveratrol and Oxyresveratrol Loaded Nanosponges. Dhakar NK; Matencio A; Caldera F; Argenziano M; Cavalli R; Dianzani C; Zanetti M; López-Nicolás JM; Trotta F Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31635183 [TBL] [Abstract][Full Text] [Related]
47. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. Malacco E; Omboni S; Mallion JM; Volpe M; High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666 [TBL] [Abstract][Full Text] [Related]
48. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. Heagerty AM; Mallion JM Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515 [TBL] [Abstract][Full Text] [Related]
49. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system. Kang MJ; Kim HS; Jeon HS; Park JH; Lee BS; Ahn BK; Moon KY; Choi YW Drug Dev Ind Pharm; 2012 May; 38(5):587-96. PubMed ID: 21988221 [TBL] [Abstract][Full Text] [Related]
50. A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Ogihara T; Saruta T; Shimada K; Kuramoto K Hypertens Res; 2009 Dec; 32(12):1148-54. PubMed ID: 19816505 [TBL] [Abstract][Full Text] [Related]
51. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan. Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and Characterization of Carboxymethyl Chitosan Nanosponges with Cyclodextrin Blends for Drug Solubility Improvement. Rizvi SSB; Akhtar N; Minhas MU; Mahmood A; Khan KU Gels; 2022 Jan; 8(1):. PubMed ID: 35049590 [TBL] [Abstract][Full Text] [Related]
53. Enhanced oral bioavailability of 10-hydroxycamptothecin through the use of poly (n-butyl cyanoacrylate) nanospheres. Jin X; Asghar S; Zhu X; Chen Z; Liu J; Li Y; Li H; Ping Q; Xiao Y Drug Dev Ind Pharm; 2017 Oct; 43(10):1637-1647. PubMed ID: 28481657 [TBL] [Abstract][Full Text] [Related]
54. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs. Li T; Geng T; Md A; Banerjee P; Wang B Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109 [TBL] [Abstract][Full Text] [Related]
55. Quercitrin loaded cyclodextrin based nanosponge as a promising approach for management of lung cancer and COVID-19. Abou Taleb S; Moatasim Y; GabAllah M; Asfour MH J Drug Deliv Sci Technol; 2022 Nov; 77():103921. PubMed ID: 36338534 [TBL] [Abstract][Full Text] [Related]